Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT

Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. Af...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jinhua, Lin, QiaoXian, Chen, Qi, Xu, Jingjing, Chen, Dabin, Chen, Renli, Lin, Kangni, Zhu, Haojie, Ye, Chenjing, Luo, Xiaofeng, Chen, Shaozhen, Kong, Hui, Lin, Qiong, Li, Nan, Lin, Xu, Chen, Zhizhe, Hu, Jianda, Yang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014299/
https://www.ncbi.nlm.nih.gov/pubmed/36936790
http://dx.doi.org/10.1016/j.isci.2023.106290
Descripción
Sumario:Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA（87.5%） and HBsAg（11.1%%）cleared in HBsAg+ patients. All HBsAg- patients acquired HBsAb immediately. Nevertheless, HBsAb titers subsequently declined, and 39/67 (58.2%) patients lost HBsAb during follow-up. The 5-year overall survival (OS) was better in patients who lost HBsAb. Multivariate analysis showed that the independent risk factors for OS were lack of cytomegalovirus (CMV) clearance, acute graft-versus-host disease (aGVHD), and no HBsAb loss. Overall, adoptive immune transfer offers anti-HBV protection to patients without HBsAb, as they acquire HBsAb and clear HBV-DNA and HBsAg, while HBsAb loss after allo-HSCT predicts better survival.

Ejemplares similares